Back to top
more

Clearside Biomedical (CLSD)

(Real Time Quote from BATS)

$1.33 USD

1.33
121,346

+0.02 (1.53%)

Updated May 20, 2024 02:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CLSD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Clearside Biomedical, Inc. [CLSD]

Reports for Purchase

Showing records 201 - 220 ( 273 total )

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 201

08/08/2019

Daily Note

Pages: 19

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 202

08/08/2019

Company Report

Pages: 9

Q2 Financials; Plans to Out-License XIPERE - Cash Runway Extended into Q3:20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 203

08/02/2019

Daily Note

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 204

08/01/2019

Company Report

Pages: 10

Presentations on SCS-Microinjection Applications at ASRS

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 205

07/29/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 206

07/29/2019

Daily Note

Pages: 9

XIPERE /ME-NIU October 19 PDUFA: We Anticipate Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 207

07/26/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 208

07/19/2019

Industry Report

Pages: 10

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 209

07/18/2019

Company Report

Pages: 8

Multiple Presentations on SCS-Microinjection Applications at OIS - ASRS

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 210

07/10/2019

Company Report

Pages: 8

License Agreement with Aura Extends SCS Platform into Ocular Oncology

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 211

07/10/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 212

05/09/2019

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 213

05/09/2019

Company Report

Pages: 7

Q1: Cash Runway into Q1:20 Covers Likely XIPERE(TM) Approval in October

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 214

04/26/2019

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 215

04/24/2019

Daily Note

Pages: 6

Multiple Presentations Support SCS-Microinjection Applications In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 216

04/18/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 217

03/18/2019

Company Report

Pages: 9

Q4/FY18 Financials; XIPERE ME-NIU Oct 19 PDUFA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 218

02/21/2019

Company Report

Pages: 9

XIPERE ME-NIU NDA Accepted by FDA; PDUFA Date Set to October 19, 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 219

01/28/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 220

01/27/2019

Daily Note

Pages: 8

ME-NIU NDA Submitted; We Anticipate FDA Acceptance of Filing in Q1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party